Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Microsporidiosis

2

Unknown

2,578

Pain

614

Cancer

592

Hypertension

567

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Previously Marketed

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Methionine aminopeptidase 2

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1953

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Sanofi-Aventis

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

EPA CompTox

2

FDA UNII

2

MERCK INDEX

2

NCI_THESAURUS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIPROTOZOALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other agents against amoebiasis and other protozoal diseases

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

FUMAGILLIN

7OW73204U1

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1953

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Methionine aminopeptidase 2

Conditions:

Microsporidiosis

Fumagillin, an antimicrobial compound first isolated in 1949 from the fungus Aspergillus fumigatusa, naturally occurring water-insoluble antibacterial agent developed by sanofi-aventis, is approved in France for the treatment of microsporidiosis. Fum...

agillin (Flisint, Sanofi-Aventis, Paris, France) has been approved in France since 2002 for the treatment of intestinal microsporidiosis due to E. bieneusi in patients with AIDS, and is also available through an expanded access program for patients without AIDS. It has not been approved, however, by the US Food and Drug Administration. The discovery of fumagillin, a MetAP-2 inhibitor, with potent antiangiogenic and antiproliferative activities promoted the development of fumagillin analogues as a novel class of anticancer agents. It has been the subject of research in cancer treatments by employing its angiogenesis inhibitory properties.

BICYCLOHEXYLAMMONIUM FUMAGILLIN

0W72P6E6EY

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1953

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Methionine aminopeptidase 2

Conditions:

Microsporidiosis

Fumagillin, an antimicrobial compound first isolated in 1949 from the fungus Aspergillus fumigatusa, naturally occurring water-insoluble antibacterial agent developed by sanofi-aventis, is approved in France for the treatment of microsporidiosis. Fum...

agillin (Flisint, Sanofi-Aventis, Paris, France) has been approved in France since 2002 for the treatment of intestinal microsporidiosis due to E. bieneusi in patients with AIDS, and is also available through an expanded access program for patients without AIDS. It has not been approved, however, by the US Food and Drug Administration. The discovery of fumagillin, a MetAP-2 inhibitor, with potent antiangiogenic and antiproliferative activities promoted the development of fumagillin analogues as a novel class of anticancer agents. It has been the subject of research in cancer treatments by employing its angiogenesis inhibitory properties.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1